 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
periplasmic space
|
2 terms
|
 |
|
Biological process
|
response to drug
|
3 terms
|
 |
|
Biochemical function
|
protein binding
|
3 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
45:3222-3234
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure-based approach for binding site identification on AmpC beta-lactamase.
|
|
R.A.Powers,
B.K.Shoichet.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Beta-lactamases are the most widespread resistance mechanism to beta-lactam
antibiotics and are an increasing menace to public health. Several
beta-lactamase structures have been determined, making this enzyme an attractive
target for structure-based drug design. To facilitate inhibitor design for the
class C beta-lactamase AmpC, binding site "hot spots" on the enzyme
were identified using experimental and computational approaches. Experimentally,
X-ray crystal structures of AmpC in complexes with four boronic acid inhibitors
and a higher resolution (1.72 A) native apo structure were determined. Along
with previously determined structures of AmpC in complexes with five other
boronic acid inhibitors and four beta-lactams, consensus binding sites were
identified. Computationally, the programs GRID, MCSS, and X-SITE were used to
predict potential binding site hot spots on AmpC. Several consensus binding
sites were identified from the crystal structures. An amide recognition site was
identified by the interaction between the carbonyl oxygen in the R1 side chain
of beta-lactams and the atom Ndelta2 of the conserved Asn152. Surprisingly, this
site also recognizes the aryl rings of arylboronic acids, appearing to form
quadrupole-dipole interactions with Asn152. The highly conserved
"oxyanion" hole defines a site that recognizes both carbonyl and
hydroxyl groups. A hydroxyl binding site was identified by the O2 hydroxyl in
the boronic acids, which hydrogen bonds with Tyr150 and a conserved water. A
hydrophobic site is formed by Leu119 and Leu293. A carboxylate binding site was
identified by the ubiquitous C3(4) carboxylate of the beta-lactams, which
interacts with Asn346 and Arg349. Four water sites were identified by ordered
waters observed in most of the structures; these waters form extensive
hydrogen-bonding networks with AmpC and occasionally the ligand. Predictions by
the computational programs showed some correlation with the experimentally
observed binding sites. Several sites were not predicted, but novel binding
sites were suggested. Taken together, a map of binding site hot spots found on
AmpC, along with information on the functionality recognized at each site, was
constructed. This map may be useful for structure-based inhibitor design against
AmpC.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
G.J.van Westen,
J.K.Wegner,
A.Bender,
A.P.Ijzerman,
and
H.W.van Vlijmen
(2010).
Mining protein dynamics from sets of crystal structures using "consensus structures".
|
| |
Protein Sci, 19,
742-752.
|
 |
|
|
|
|
 |
S.M.Drawz,
M.Babic,
C.R.Bethel,
M.Taracila,
A.M.Distler,
C.Ori,
E.Caselli,
F.Prati,
and
R.A.Bonomo
(2010).
Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.
|
| |
Biochemistry, 49,
329-340.
|
 |
|
|
|
|
 |
S.M.Drawz,
and
R.A.Bonomo
(2010).
Three decades of beta-lactamase inhibitors.
|
| |
Clin Microbiol Rev, 23,
160-201.
|
 |
|
|
|
|
 |
D.G.Teotico,
K.Babaoglu,
G.J.Rocklin,
R.S.Ferreira,
A.M.Giannetti,
and
B.K.Shoichet
(2009).
Docking for fragment inhibitors of AmpC beta-lactamase.
|
| |
Proc Natl Acad Sci U S A, 106,
7455-7460.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Mammeri,
M.Galleni,
and
P.Nordmann
(2009).
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
|
| |
Antimicrob Agents Chemother, 53,
323-326.
|
 |
|
|
|
|
 |
Y.Chen,
A.McReynolds,
and
B.K.Shoichet
(2009).
Re-examining the role of Lys67 in class C beta-lactamase catalysis.
|
| |
Protein Sci, 18,
662-669.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Murano,
T.Yamanaka,
A.Toda,
H.Ohki,
S.Okuda,
K.Kawabata,
K.Hatano,
S.Takeda,
H.Akamatsu,
K.Itoh,
K.Misumi,
S.Inoue,
and
T.Takagi
(2008).
Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.
|
| |
Bioorg Med Chem, 16,
2261-2275.
|
 |
|
|
|
|
 |
R.B.Pelto,
and
R.F.Pratt
(2008).
Kinetics and mechanism of inhibition of a serine beta-lactamase by O-aryloxycarbonyl hydroxamates.
|
| |
Biochemistry, 47,
12037-12046.
|
 |
|
|
|
|
 |
J.M.Thomson,
F.Prati,
C.R.Bethel,
and
R.A.Bonomo
(2007).
Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.
|
| |
Antimicrob Agents Chemother, 51,
1577-1579.
|
 |
|
|
|
|
 |
P.Nordmann,
and
H.Mammeri
(2007).
Extended-spectrum cephalosporinases: structure, detection and epidemiology.
|
| |
Future Microbiol, 2,
297-307.
|
 |
|
|
|
|
 |
C.A.Bottoms,
T.A.White,
and
J.J.Tanner
(2006).
Exploring structurally conserved solvent sites in protein families.
|
| |
Proteins, 64,
404-421.
|
 |
|
|
|
|
 |
K.Babaoglu,
and
B.K.Shoichet
(2006).
Deconstructing fragment-based inhibitor discovery.
|
| |
Nat Chem Biol, 2,
720-723.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Chen,
G.Minasov,
T.A.Roth,
F.Prati,
and
B.K.Shoichet
(2006).
The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution.
|
| |
J Am Chem Soc, 128,
2970-2976.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Fenollar-Ferrer,
J.Donoso,
J.Frau,
and
F.Muñoz
(2005).
Molecular modeling of Henry-Michaelis and acyl-enzyme complexes between imipenem and Enterobacter cloacae P99 beta-lactamase.
|
| |
Chem Biodivers, 2,
645-656.
|
 |
|
|
|
|
 |
N.H.Georgopapadakou
(2004).
Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.
|
| |
Expert Opin Investig Drugs, 13,
1307-1318.
|
 |
|
|
|
|
 |
A.C.Anderson
(2003).
The process of structure-based drug design.
|
| |
Chem Biol, 10,
787-797.
|
 |
|
|
|
|
 |
J.Alba,
C.Bauvois,
Y.Ishii,
M.Galleni,
K.Masuda,
M.Ishiguro,
M.Ito,
J.M.Frere,
and
K.Yamaguchi
(2003).
A detailed kinetic study of Mox-1, a plasmid-encoded class C beta-lactamase.
|
| |
FEMS Microbiol Lett, 225,
183-188.
|
 |
|
|
|
|
 |
S.D.Goldberg,
W.Iannuccilli,
T.Nguyen,
J.Ju,
and
V.W.Cornish
(2003).
Identification of residues critical for catalysis in a class C beta-lactamase by combinatorial scanning mutagenesis.
|
| |
Protein Sci, 12,
1633-1645.
|
 |
|
|
|
|
 |
T.A.Roth,
G.Minasov,
S.Morandi,
F.Prati,
and
B.K.Shoichet
(2003).
Thermodynamic cycle analysis and inhibitor design against beta-lactamase.
|
| |
Biochemistry, 42,
14483-14491.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|